(ACB) Aurora Cannabis - Ratings and Ratios

Exchange: NASDAQ • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA05156X8843

ACB: Cannabis, Oils, Capsules, Edibles, Extracts, Vapes, CBD

Aurora Cannabis Inc. (NASDAQ:ACB) operates as a diversified cannabis company, focusing on the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. The company functions through two primary segments: Canadian Cannabis and Plant Propagation. Its product portfolio includes medical and consumer cannabis offerings, hemp-derived CBD products, and a wide range of cannabis-based goods such as dried cannabis, oils, capsules, edibles, extracts, and soft gels. These products are designed for various consumption methods, including smoking, vaporizing, and ingestion in forms like oils and capsules. Aurora also provides patient counseling and outreach services, enhancing its commitment to medical cannabis patients.

The companys adult-use cannabis brands, such as Aurora Drift, San Rafael 71, Daily Special, Whistler, Being, and Greybeard, cater to the recreational market, while its CBD brands, including Reliva and KG7, target the health and wellness sector. On the medical side, Aurora boasts a robust portfolio with brands like MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant, underscoring its dedication to providing high-quality medical cannabis products globally.

Aurora Cannabis Inc. was established in 2013 and is headquartered in Edmonton, Canada. The company has made strategic investments in research and development, particularly in extraction technologies, and has expanded its cultivation capabilities. Its focus on innovation, such as pre-roll and vapor products, aligns with evolving consumer preferences. Additionally, Aurora has strengthened its market position through acquisitions, including MedReleaf and CanniMed, enhancing its medical cannabis offerings and global distribution network.

Ticker Symbol: ACB
Exchange: NASDAQ
Type: common stock
Country Origin: Canada
GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 6944352
Last Price: 5.10
SMA 20: 5.55
SMA 50: 4.71
SMA 200: 5.41
ATR: 0.37

Market Cap: 259.17M USD
P/E: 0.00
P/E Forward: 769.23
P/B: 0.76
P/S: 0.88
RoE: 1.53

3-Month Forecast:

Based on the provided technical and fundamental data, Aurora Cannabis Inc. (ACB) is expected to experience a challenging three months. Technically, the stock is trading below its SMA20 and SMA50, indicating bearish momentum. The ATR of 0.37 suggests moderate volatility, which could lead to price swings. On the fundamental side, the high forward P/E of 769.23 reflects investor expectations for significant growth, though the current P/E of 0 indicates no earnings. The P/B ratio of 0.76 points to undervaluation relative to book value, while the P/S ratio of 0.88 suggests the stock is reasonably priced relative to sales. However, the low RoE of 1.53 raises concerns about profitability. Overall, the stock may face headwinds due to its current position relative to moving averages and mixed fundamental signals.

Additional Sources for ACB Stock

ACB Stock Overview

Market Cap in USD 259m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2014-07-11

ACB Stock Ratings

Growth 5y -86.5%
Fundamental -28.8%
Dividend 0.0%
Rel. Strength Industry 51.3
Analysts 3.67/5
Fair Price Momentum 2.47 USD
Fair Price DCF -

ACB Dividends

No Dividends Paid

ACB Growth Ratios

Growth Correlation 3m 43.8%
Growth Correlation 12m -49.1%
Growth Correlation 5y -92.4%
CAGR 5y -44.36%
CAGR/Max DD 5y -0.45
Sharpe Ratio 12m -1.30
Alpha 38.22
Beta 1.57
Volatility 71.08%
Current Volume 497.8k
Average Volume 20d 1443.3k
What is the price of ACB stocks?
As of March 15, 2025, the stock is trading at USD 4.41 with a total of 497,822 shares traded.
Over the past week, the price has changed by -7.35%, over one month by -30.11%, over three months by +2.80% and over the past year by +52.60%.
Is Aurora Cannabis a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Aurora Cannabis (NASDAQ:ACB) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.82 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACB as of March 2025 is 2.47. This means that ACB is currently overvalued and has a potential downside of -43.99%.
Is ACB a buy, sell or hold?
Aurora Cannabis has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold ACB.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ACB stock price target?
According to ValueRays Forecast Model, ACB Aurora Cannabis will be worth about 2.8 in March 2026. The stock is currently trading at 4.41. This means that the stock has a potential downside of -37.19%.
Issuer Forecast Upside
Wallstreet Target Price 32.1 627.2%
Analysts Target Price 32.1 627.2%
ValueRay Target Price 2.8 -37.2%